Wu Chih-Ying, Jan Yee-Jee, Ko Bor-Sheng, Wu Ya-Ju, Wu Yi-Ju, Liou Jun-Yang
Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
Anticancer Res. 2018 Dec;38(12):6855-6863. doi: 10.21873/anticanres.13060.
BACKGROUND/AIM: Expression of 14-3-3ε is associated with prognostic outcomes of hepatocellular carcinoma (HCC) patients. Metallothionein-1 (MT-1) proteins and aldo-keto-reductase family 1 B10 (AKR1B10) are considered potential tumor regulators of HCC. The aim of this study, was to examine the prognostic value of 14-3-3ε, MT-1 and AKR1B10 expression in HCC.
The expression levels of 14-3-3ε, MT-1 and AKR1B10 in HCC cell lines and paraffin-embedded tissues were examined by western blotting and immunohistochemical analysis.
14-3-3ε positivity was significantly associated with decreased MT-1 expression in HCC. Patients with decreased MT-1 expression had worse survival rates and a higher risk of metastasis than 14-3-3ε-positive HCC patients with unchanged MT-1 expression. Distinct expression patterns of 14-3-3ε/MT-1/AKR1B10 were significantly associated with the metastatic incidence and survival rates of HCC patients. Patients with negative 14-3-3ε staining in primary tumors had better prognostic outcomes. In contrast, patients with positive 14-3-3ε staining, decreased MT-1 expression and no increase in AKR1B10 expression in primary tumors had the worst overall and disease-free survival rates and the highest metastatic risk.
14-3-3ε, AKR1B10, and MT-1 act as potential prognostic biomarkers of HCC.
背景/目的：14-3-3ε的表达与肝细胞癌（HCC）患者的预后结果相关。金属硫蛋白-1（MT-1）蛋白和醛糖还原酶家族1B10（AKR1B10）被认为是HCC潜在的肿瘤调节因子。本研究的目的是检测14-3-3ε、MT-1和AKR1B10在HCC中的表达的预后价值。
通过蛋白质免疫印迹法和免疫组织化学分析法检测HCC细胞系及石蜡包埋组织中14-3-3ε、MT-1和AKR1B10的表达水平。
在HCC中，14-3-3ε阳性与MT-1表达降低显著相关。MT-1表达降低的患者比MT-1表达未改变的14-3-3ε阳性HCC患者生存率更差且转移风险更高。14-3-3ε/MT-1/AKR1B10的不同表达模式与HCC患者的转移发生率和生存率显著相关。原发肿瘤中14-3-3ε染色阴性的患者预后更好。相反，原发肿瘤中14-3-3ε染色阳性、MT-1表达降低且AKR1B10表达未增加的患者总生存率和无病生存率最差，转移风险最高。
14-3-3ε、AKR1B10和MT-1可作为HCC潜在的预后生物标志物。
